Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Glox Therapeutics has appointed of Michael Murray as chair of its board. He will work with the leadership team to accelerate ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

A TV commercial that the telehealth company Hims & Hers Health (NYSE:HIMS) is planning to run during the upcoming Super Bowl LIX coverage to promote its compounded weight loss products has drawn ...

Shares of Hims & Hers Health (NYSE:HIMS) rallied to reach an all-time high on Friday as the telehealth firm is set to debut its controversial TV commercial 'Sick of the System' during the upcoming ...

Ozempic and Wegovy has been prescribed to Yorkshire patients hundreds of times in the past year - and it's not for weightloss.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.